Israeli biotech company Cell Cure Neurosciences, a subsidiary of biotech giant BioTime, has announced that it has received a $1.33 million grant from The Israeli Chief Scientist Office.
The company says that it will use the funds to finance the development of its latest product, OpRegen, a cell-based treatment for macular degeneration, an age-related condition that impairs vision. The company has also announced that it will apply for human trials of the treatment this year.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments